Department of Clinical Nutrition, Suining Central Hospital, Suining, China.
Department of Oncology, Suining Central Hospital, Suining, China.
Int J Clin Pract. 2022 Jul 8;2022:6564466. doi: 10.1155/2022/6564466. eCollection 2022.
Radiotherapy and chemotherapy in patients with lung cancer can lead to a series of problems such as malnutrition and inflammatory reaction. Some studies have shown that -3 polyunsaturated fatty acids (PUFAs) could improve malnutrition and regulate inflammatory reaction in these patients, but no relevant meta-analysis exists.
We systematically searched randomized controlled trials of -3 PUFAs in the adjuvant treatment of lung cancer in the PubMed, EMBASE, Cochrane Library, Web of Science, Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), and Wanfang databases. Relevant outcomes were extracted, and we pooled standardized mean differences (SMDs) using a random or fixed-effects model. The risk of bias was evaluated according to the Cochrane Handbook (version 15.1). The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE).
A total of 7 studies were included. The SMDs (95% CI) of body weight change, albumin change, energy intake, and protein intake at the end of intervention were 1.15 (0.50, 1.80), 0.60 (0.11, 1.09), 0.39 (-0.10, 0.89), and 0.27 (-0.04, 0.58), respectively. The SMDs (95% CI) of CRP change and TNF- change were -3.44 (-6.15, -0.73) and -1.63 (-2.53, -0.73), respectively.
-3 PUFAs can improve nutritional status and regulate indicators of inflammation in patients with lung cancer undergoing radiotherapy and chemotherapy. This study was registered in the PROSPERO (registration number: CRD42022307699).
肺癌患者接受放化疗后可出现营养不良、炎症反应等一系列问题。有研究表明，ω-3 多不饱和脂肪酸（PUFA）可改善此类患者的营养不良并调节炎症反应，但目前尚缺乏相关的 Meta 分析。
我们系统检索了 PubMed、EMBASE、Cochrane 图书馆、Web of Science、中国生物医学文献数据库（CBM）、中国知网（CNKI）和万方数据库中关于 ω-3 PUFA 辅助治疗肺癌的随机对照试验。提取相关结局指标，采用固定或随机效应模型进行标准化均数差（SMD）的合并。根据 Cochrane 手册（第 15.1 版）评估偏倚风险，采用 Grading of Recommendations Assessment, Development, and Evaluation（GRADE）评估证据质量。
共纳入 7 项研究。干预结束时体重变化、白蛋白变化、能量摄入和蛋白质摄入的 SMD（95%CI）分别为 1.15（0.50，1.80）、0.60（0.11，1.09）、0.39（-0.10，0.89）和 0.27（-0.04，0.58），C 反应蛋白变化和肿瘤坏死因子-α变化的 SMD（95%CI）分别为-3.44（-6.15，-0.73）和-1.63（-2.53，-0.73）。
ω-3 PUFA 可改善放化疗肺癌患者的营养状况，调节炎症指标。本研究已在 PROSPERO 注册（注册号：CRD42022307699）。
